Recent studies suggest that patients with metastatic melanoma who progress on PD-L1-directed therapy can respond to combined PD-L1 and CTLA-4 inhibition [44], but it is still not clear the clinical impact of this combination in terms of safety. This evidence concerns the gene CTLA4 and metastatic melanoma.